Expansion of extracellular matrix with fibrosis occurs in many tissues as part of the end-organ complications in diabetes, and advanced glycosylation end products (AGE) are implicated as one causative factor in diabetic tissue fibrosis. Connective tissue growth factor (CTGF), also known as insulin-like growth factor-binding proteinrelated protein-2 (IGFBP-rP2), is a potent inducer of extracellular matrix synthesis and angiogenesis and is increased in tissues from rodent models of diabetes. The aim of this study was to determine whether CTGF is up-regulated by AGE in vitro and to explore the cellular mechanisms involved. AGE treatment of primary cultures of nonfetal human dermal fibroblasts in confluent monolayer increased CTGF steady state messenger RNA (mRNA) levels in a time-and dose-dependent manner. In contrast, mRNAs for other IGFBP superfamily members, IGFBP-rP1 (mac 25) and IGFBP-3, were not up-regulated by AGE. The effect of the AGE BSA reagent on CTGF mRNA was due to nonenzymatic glycosylation of BSA and, using neutralizing antisera to AGE and to the receptor for AGE, termed RAGE, was seen to be due to late products of nonenzymatic glycosylation and was partly mediated by RAGE. Reactive oxygen species as well as endogenous transforming growth factor-␤1 could not explain the AGE effect on CTGF mRNA. AGE also increased CTGF protein in the conditioned medium and cell-associated CTGF. Thus, AGE up-regulates the profibrotic and proangiogenic protein CTGF (IGFBP-rP2), a finding that may have significance in the development of diabetic complications. (Endocrinology 142: 1760 -1769, 2001) 
M ULTIPLE MECHANISMS have been described by which chronic hyperglycemia might contribute to the pathological end-organ complications that occur in diabetes mellitus. These include direct effects of elevated glucose on cells, hyperosmolality, oxidant stress, and nonenzymatic glycosylation (1, 2) . Advanced glycosylation end products (AGE) are biochemical end products of nonenzymatic glycosylation that are formed irreversibly (3) . AGE is elevated in serum (4) and in many tissues in patients with diabetes (5), including skin (6) , and has the ability to covalently cross-link and biochemically modify protein structure and affect protein function (7) . Additionally, in recent years cell surface receptors for AGE have been identified (8) , and postreceptor signaling pathways are being defined (9, 10) . Through an AGE receptor-dependent mechanism, AGE induction of cytokines and growth factors has been implicated in contributing to end-organ changes that occur in tissues in patients with diabetes (11) (12) (13) .
Pathological hallmarks in most tissues where diabetes complications occur include expansion of extracellular matrix (ECM) and angiogenesis (1) . The ECM expansion has been proposed to be due to a combination of increased ECM production (14) (15) and biochemically modified matrix, with a reduction in ECM breakdown (16) . Connective tissue growth factor (CTGF), also known as insulin-like growth factor (IGF)-binding protein-related protein-2 (IGFBP-rP2) (17) , is a potent inducer of ECM in fibroblasts (18, 19) and a potent angiogenic factor (20, 21) . A potential role for CTGF in fibrotic disease states is increasingly being described (22) (23) (24) , suggesting that CTGF may be a mediator of ECM expansion and fibrosis in diabetes. The aim of this study was to determine whether CTGF is up-regulated by AGE and subsequently to explore the cellular mechanism(s) that might be responsible for this effect.
was a gift from Dr. H. Miyata, Kissei Pharmaceutical Co. Ltd. (Nagano, Japan). The antihuman polyclonal antibody generated in rabbits against the receptor for AGE (RAGE) was provided as an IgG fraction (gift from Dr. A.M. Schmidt, Columbia University, New York, NY). This antibody inhibits ligand-stimulated activation of RAGE by AGE (27, 28) . The transforming growth factor-␤1 (TGF␤1) affinity-purified IgG antibody generated in chickens that neutralizes TGF␤1 bioactivity was purchased from R&D Systems, Inc. (Minneapolis, MN). Nonimmune rabbit IgG, d-glucose, glycolaldehyde, BSA (fraction V, fatty acid and endotoxin free), and aminoguanidine were purchased from Sigma (St. Louis, MO). TGF␤1 was purchased from Austral Biologicals (San Ramon, CA).
Intact carboxyl-terminal flag-tagged IGFBP-rP2 (CTGF), used as a standard in the Western immunoblots and in the CTGF enzyme-linked immunosorbent assay (ELISA), was purified from a baculovirus expression system, and pure IGFBP-rP2 (CTGF) protein was quantitated using Coomassie-stained gels with BSA as standard, all as previously described (29) . The approximately 14-kDa fragment of IGFBP-rP2 (CTGF), described in Fig. 7A , was purified from a highly proteolyzed preparation of pure IGFBP-rP2 (CTGF) protein, using late-harvested SF-9 insect cell lysates. After initial purification of this preparation by means of flag protein-Sepharose affinity chromatography (29) , the fragment was separated from any remaining intact IGFBP-rP2 (CTGF) using a high performance size-fractionation gel permeation column (HR-75, Pharmacia Biotech, Piscataway, NJ) with PBS as buffer, with fast performance liquid chromatography, eluting at 0.5 ml/min with 0.5-ml fractions. Pure, approximately 14-kDa fragment was confirmed by Coomassie staining and Western immunoblot using IGFBP-rP2 (CTGF) primary antibody (not shown).
AGE synthesis
Advanced glycosylation end products were synthesized in vitro, following methods previously described (26, 30, 31) . BSA (Sigma, RIA grade, fraction V) at 10 mm was coincubated in sterile PBS with either 0.5 m d-glucose for 10 weeks or 25 mm glycolaldehyde for 3 days, each with 1.5 mm phenylmethylsulfonylfluoride under aerobic conditions at 37 C. To generate control BSA for comparison with AGE treatments, tubes were prepared with simultaneous incubations under the same conditions without the addition of the respective reducing sugar or aldehyde. Additionally, in parallel preparations, aminoguandine at 100 mm, as an inhibitor of formation of products of nonenzymatic glycosylation (13) , was added to the BSA and glucose. All preparations were extensively dialyzed in PBS, using a low M r cut-off membrane (6 -8 kDa, Spectrapor 1, Spectrum Industries, Los Angeles, CA) (13) .
The AGE content in the preparations was assessed by means of fluorescence, SDS-PAGE analysis, and ELISA. The fluorescence content, measured with a fluorescence spectrometer at 390 nm emission after 450 nm excitation in relative fluorescence units per mg BSA, was 11.2 Ϯ 2.5 for control BSA, 67.1 Ϯ 12.5 for AGE BSA from glycolaldehyde, 52.3 Ϯ 6.3 for AGE BSA from glucose, and 9.7 Ϯ 1.2 for aminoguanidine added to BSA and glucose (termed aminoguanidine BSA) (31) . By SDS-PAGE analysis under reducing conditions, followed by Coomassie staining, the AGE BSA produced from d-glucose and glycolaldehyde was shown to have high M r species consistent with the intermolecular cross-linking ability of AGE, as previously described (26) . In contrast, the control BSA and aminoguanidine BSA preparations did not have these high M r forms (data not shown). By competitive ELISA (32), performed by Dr. P. Foiles (Alteon, Inc., Ramsey, NJ), using a synthetic N-⑀-carboxymethyl lysine (CML) analog as the standard, the CML content of the preparations (picomoles of CML per g BSA Ϯ 95% confidence interval) was 82 Ϯ 8.5 for AGE BSA from glycolaldehyde and 13 Ϯ 1.4 for AGE BSA from glucose and was undetectable (Ͻ1) for control BSA and also undetectable when aminoguanidine at 100 mm was coincubated with BSA and glucose. Unless otherwise indicated in the text, the data described refer to the use of AGE BSA synthesized from glucose.
Cell culture
Primary cell cultures of nonfetal human dermal fibroblasts, CRL-2097 and CRL-1474, were purchased from American Type Culture Collection (Manassas, VA). Cells were maintained in MEM supplemented with 10% FBS and were used in these studies between passages 4 and 12. The human primary cultures of dermal fibroblasts, designated A35 (derived from the forearm of a 70-yr-old male) and A305 (newborn foreskin fibroblasts), were gifts from Dr. S. Goldstein, Memorial Veteran's Hospital (Little Rock, AR). These cells were maintained in DMEM with 15% FBS.
Cell treatment
After trypsinization, cells were grown in 12-well plates for 5 days in their respective media with FBS until they were confluent. For experiments requiring the use of blocking antibodies to RAGE and AGE, cells were grown in 24-well plates under the same conditions. Cells were then incubated in their respective serum-free medium for 16 h and then treated with additions on day 0 under serum-free conditions, using fresh media. Unless otherwise indicated in the text, the conditioned media were not changed after adding the treatments. When cells were transiently treated for 8 h with reagents, they were washed with PBS, and fresh serum-free medium with 0.05% BSA was added. Cell lysates and conditioned media were harvested up to 3 days after treatments. For experiments involving the use of blocking antibodies or antioxidants, cells were preincubated with the antibody or reagent for 2 h under serum-free conditions before adding AGE or control BSA directly to the medium.
Total RNA isolation and analysis by quantitative real-time RT-PCR
Total RNA was isolated from duplicate wells using the RNeasy Minikit from QIAGEN (Valencia, CA) and was then analyzed by quantitative real-time PCR using an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA). This system is based on the ability of the 5Ј-nuclease activity of Taq polymerase to cleave a nonextendable dual labeled fluorogenic hybridization probe during the extension phase of PCR. The following sequence-specific primers and probes for human CTGF, IGFBP-rP1, IGFBP-3, and 18S ribosomal RNA were designed using Primer Express Software 1.0 (PE Applied Biosystems): for CTGF: forward, 5Ј-GAGGAAAACATTAAGAAGGGCAAA-3Ј; reverse, 5Ј-CG-GCACAGGTCTTGATGA-3Ј; and probe, 5Ј-6FAM-TTTGAGCTTTCTG-GCTGCACCAGTGT-TAMRA-3Ј; for IGFBP-rP1: forward, 5Ј-GCG-GAAAATGGCAGACAATT-3Ј; reverse, 5Ј-CTTGAGGGTTTGGGTT-TCCA-3Ј; and probe, 5Ј-6FAM-TTCGCTCCATGATGCGTTATCTGGG-TAMRA-3Ј; for IGFBP-3: forward, 5Ј-AAGGTGGGTAGGCACGTTG-TAG-3Ј; reverse, 5Ј-ATATCAAAACCCGAATCCACTTTACT-3Ј; and probe, 5Ј-6FAM-CAAAGCAATGTCTAGTCCCGGTATGTCCAA-TA-MRA-3Ј; for 18S: forward, 5Ј-CGGCTACCACATCCAAGGAA-3Ј; reverse, 5Ј-GCTGGAATTACCGCGGCT-3Ј; and probe, 5Ј-6FAM-TGCT-GGCACCAGACTTGCCCTC-TAMRA-3Ј. Primers were used at a concentration of 200 nm and probes at 100 nm in each reaction. Multiscribe reverse transcriptase and AmpliTaq Gold polymerase (PE Applied Biosystems) were used in all RT-PCR reactions. Each RNA sample was analyzed in triplicate. Relative quantitation of 18S ribosomal RNA and human CTGF, IGFBP-rP1, and IGFBP-3 messenger RNAs (mRNAs) was calculated using the comparative threshold cycle number for each sample fitted to a five-point standard curve (ABI prism 7700 User Bulletin 2, PE Applied Biosystems). The standard curve was constructed using a serial dilution of total RNA extracted from human cardiac fibroblasts that had been treated with TGF␤1 at 1 ng/ml for 24 h. Expression levels were normalized to 18S ribosomal RNA and related to relevant controls, as indicated in the text.
Preparation of conditioned media and cell lysates
Cell lysate samples were harvested after treatment, by washing cells with PBS, then adding 100 l cold RIPA lysis buffer [20 mm Tris (pH 8.0), 150 mm NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS] plus a protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany) directly to each well. Plates were rocked for 15 min at 4 C, and lysates were collected and centrifuged at 10,000 ϫ g for 10 min at 4 C. The supernatants from duplicate wells within each experiment were pooled and stored at Ϫ20 C until analysis. The total protein concentration was determined for each sample by use of the DC Protein Assay reagent (Bio-Rad Laboratories, Inc., Hercules, CA). Then 20 g total protein were loaded per lane for SDS-PAGE analysis, and 5 g total protein were added to each ELISA well for CTGF quantitation.
Western immunoblot analysis
Conditioned medium samples were separated on 15% nonreducing SDS-PAGE. Proteins were electrotransferred onto nitrocellulose, and membranes were blocked with 5% nonfat dry milk/TBS with 0.1% (vol/vol) Tween 20 for 1 h at 22 C, then incubated in IGFBP-rP2 (CTGF) antiserum at 1:1000 dilution at 4 C overnight. After incubation of membranes with a horseradish peroxidase (HRP)-labeled secondary antibody for 1 h at 22 C, immunoreactive proteins were detected by use of enhanced chemiluminescence (NEN Life Science Products, Boston, MA).
CTGF (IGFBP-rP2) ELISA
The anti-IGFBP-rP2 (CTGF) antibody (8800) (25) was biotinylated by incubating protein A affinity-purified 8800 (0.8 g) with 150 g sulfo-NHS-LC biotin (Pierce Chemical Co., Rockford, IL) for 2 h at 22 C, followed by separation from unreacted biotin through a size-fractionation and desalting column with PBS as buffer according to the manufacturer's instructions. Affinity-purified 8800 antibody (600 ng/well) in 10 mm sodium carbonate, pH 9.6, was adsorbed to 96-well immunoplates (Nalge Nunc International, Rochester, NY) by a 20-h incubation at 4 C. The unbound antibody was removed, and the wells were blocked by incubation with PBS and 0.1% (vol/vol) Triton X-100 (buffer A) containing 10 g/liter BSA for 2 h at 37 C, then washed four times with buffer A. Purified intact recombinant human (rh) IGFBP-rP2 (CTGF) in buffer A and 1 g/liter BSA was used to generate standard curves. Standard and samples (100 l/well) were incubated in duplicate at 4 C for 20 h. The plate was washed, then incubated with biotinylated IGFBPrP2 (CTGF) antibody (80 ng/well) for 20 h at 4 C. After washing, the plate was incubated with streptavidin-HRP (1:500) for 30 min at 22 C, followed by substrate [0.1 g/liter 3,3Ј,5,5Ј-tetramethylbenzidine in 0.2 m sodium acetate (pH 6) containing 0.06% (wt/wt) H 2 O 2 ] for 30 min at 22 C. The reaction was stopped by the addition of 2 m H 2 SO 4 , and the absorbance was measured at 450 nm using a microplate reader. The interassay coefficient of variation was 8.1% for the middle concentration (10 ng/ well) of rhIGFBP-rP2 (CTGF) standard used. No cross-reactivity was detected with 1 g/well purified rhIGFBP-3, rhIGFBP-rP1 (mac 25), or rhIGFBP-rP3 (Nov H; not shown).
CTGF (IGFBP-rP2) cell association assay
To determine whether increases in rhIGFBP-rP2 (CTGF) in the whole cell lysates after AGE treatment are due to increases in rhIGFBP-rP2
Time-course induction of CTGF (IGFBP-rP2) mRNA by AGE BSA. Soluble AGE BSA at 100 g/ml was added to duplicate wells of confluent primary cultures of human fibroblasts (CRL-2097 cells) under serum-free conditions, and total RNA was collected at the time points shown. Control BSA at the same concentration was added to other wells, also in duplicate. CTGF mRNA was then determined by quantitative RT-PCR in triplicate for each sample, as described in Materials and Methods. The CTGF mRNA level is expressed in arbitrary units normalized to 18S. A, Time course up to 24 h. B, Time course from 1-3 days. C, Treatment for 8 h only with AGE BSA or control BSA at 100 g/ml, followed by RNA analysis on days 1-3. Data in A-C are the mean Ϯ 1 SD from three independent experiments. *, P Ͻ 0.05 vs. the respective control BSA. (CTGF) at a cell-associated site either on the cell surface or in the extracellular matrix, rather than intracellularly, 2097 fibroblasts in confluent monolayer were treated under serum-free conditions with AGE or control BSA (each at 100 g/ml) for 3 days in replicates of four. After washing twice with PBS at 4 C, biotinylated rhIGFBP-rP2 (CTGF) antibody (800 ng/well) together with streptavidin-HRP (1:500) was added for 2 h at 22 C in PBS and 0.1% BSA. In some wells the streptavidin-HRP (1:500) was added in the absence of primary antibody to determine nonspecific binding and endogenous cellular peroxidase activity. After two further (gentle) PBS washes, developing substrate was added, and absorbance was read as described for the IGFBP-rP2 (CTGF) ELISA above.
Densitometric analysis
To quantify the relative induction of CTGF after Western immunoblots, densitometric measurement was performed using GS-700 Imaging Densitometer with Mutli-Analyst Software (Bio-Rad Laboratories, Inc.).
Statistical analysis
Results are expressed as the mean Ϯ sd or the mean Ϯ sem as indicated in the text. All data were pooled from three or four independent experiments, each performed in triplicate. Differences between groups were assessed using Student's two-tailed paired t test in Excel 98 (Microsoft Corp., Redmond, WA). P Ͻ 0.05 was considered statistically significant.
Results
To determine whether CTGF mRNA steady state levels are up-regulated by AGE in primary cultures of human dermal fibroblasts, confluent monolayers of CRL-2097 fibroblasts were treated with soluble AGE BSA under serum-free conditions. In response to 100 g/ml AGE BSA, an increase in CTGF mRNA was initially detectable after 8 h of AGE treatment (Fig. 1A) , and a progressive increase occurred over the 3-day time course of the study (Fig. 1B) . In contrast, no change in CTGF mRNA over time was seen with the same concentration of control BSA (Fig. 1, A and B) . These results were confirmed by Northern analysis (not shown). Transient treatment of cells with AGE for 8 h, followed by washing of cells with PBS and replacement with fresh serum-free medium, also caused a progressive increase in CTGF mRNA over subsequent days (Fig. 1C) , with a clear persistence of the effect for at least 72 h after AGE addition.
A dose-response study with AGE BSA from 0 -200 g/ml, with continuous AGE treatment and RNA collection at 48 h after initial AGE addition, showed that increases in CTGF mRNA were significant using 10 g/ml or more AGE BSA, whereas increasing concentrations of control BSA did not produce any change in CTGF mRNA compared with no addition of BSA (Fig. 2) .
Primary human skin fibroblasts from other donors were studied to assess whether the changes seen in CTGF mRNA in human foreskin fibroblast CRL-2097 cells are generalizable to human dermal fibroblasts. When these other cells were treated with 100 g/ml AGE BSA, increases in CTGF mRNA were observed 48 h after treatment, compared with the control BSA, in all of the fibroblast cell lines studied whether they were derived from neonatal foreskin (A305), a child's abdomen (CRL-1474), or the forearm of a mature adult (A35; Fig. 3A) .
To address whether the changes seen in CTGF mRNA were relatively specific, other members of the IGFBP superfamily were analyzed in the same cell system. In contrast to the observed regulation of CTGF mRNA by AGE, IGFBP-rP1 (mac 25) mRNA was not up-regulated by AGE BSA (Fig. 3B) . IGFBP-3 is the predominant IGFBP present in human fibro- FIG. 3 . Generalizability of the AGE BSA effect on CTGF (IGFBP-rP2) mRNA to multiple sources and donors of human skin fibroblasts, and specificity of the effect to CTGF (IGFBP-rP2). A, Soluble AGE BSA or control BSA at 100 g/ml was added to duplicate wells of confluent primary cultures of human skin fibroblasts from multiple donors under serum-free conditions, and total RNA was collected at the time points shown. IGFBP-rP2 (CTGF) mRNA was then determined by quantitative RT-PCR in triplicate for each sample. The IGFBP-rP2 (CTGF) mRNA level is expressed in arbitrary units, normalized to 18S. The donor age and skin site of the fibroblasts studied are: 7-yr-old male abdomen (CRL-1474 cells), 70-yr-old male forearm (A35), and newborn foreskin (A305). Data are the mean Ϯ 1 SD from three independent experiments. B, Soluble AGE BSA or control BSA at 100 g/ml or TGF␤1 at 1 ng/ml was added to duplicate wells of confluent primary cultures of human fibroblasts (CRL-2097) under serum-free conditions. Total RNA was collected at 48 h, and CTGF (IGFBP-rP2) mRNA, IGFBP-rP1 (mac-25) mRNA, and IGFBP-3 mRNA levels were determined by quantitative RT-PCR in triplicate for each sample. The mRNA levels are expressed in arbitrary units. Data are the mean Ϯ 1 SD from three independent experiments. *, P Ͻ 0.05; **, P Ͻ 0.01 (vs. the respective control BSA).
blast conditioned medium (33) , and its mRNA also was not increased by AGE (Fig. 3B ). In comparison with the lack of effect of AGE treatment, TGF␤1 treatment modestly upregulated IGFBP-rP1, and possibly IGFBP-3 mRNA, at 48 h (Fig. 3B) , as previously described (33, 34) . Also consistent with previous observations in cultured human fibroblasts (35) , a pronounced up-regulation of CTGF mRNA occurred after TGF␤1 addition (Fig. 3B) .
Formation of products of nonenzymatic glycosylation was inhibited by the dihydrazine compound, aminoguanidine (13) . When cells were treated with BSA that had been coincubated for 10 weeks with both glucose and aminoguanidine as described in Materials and Methods, no increase in CTGF mRNA was observed compared with control BSA treatment alone or with serum-free medium without any addition (Fig. 4A) . This result confirms that the active component in the AGE reagent used is a product of nonenzymatic glycosylation.
To determine whether early or advanced glycosylation end products are mediating the effect on CTGF in this cell system, cells were preincubated with anti-AGE IgG before addition of the AGE reagent. Using the anti-AGE antibody, the AGE induction of CTGF mRNA was inhibited, on the average, by 86.2% (Fig. 4B ). As this antibody is specific to AGE and it does not bind to amadori products (26) , which are early products of nonenzymatic glycosylation, these results show that AGE is the active component in the synthesized reagent responsible for increasing CTGF in these studies.
AGE may bind to and activate one or more of the defined cell surface receptors for AGE (8) . The AGE receptor subtype, termed RAGE, has recently been shown to be present on the surface of human fibroblasts (27) , and in some cell systems the induction of growth factors by AGE has been shown to be mediated by RAGE (36) . When cells were preincubated with a blocking antibody of RAGE activation by AGE ligand, the induction of CTGF mRNA by AGE was attenuated by the   FIG. 4 . The AGE effect on CTGF (IGFBP-rP2) occurs through nonenzymatic glycosylation of BSA, is blocked by an anti-AGE-neutralizing antibody, is partially mediated through the AGE receptor, RAGE, and is not inhibited by oxygen free radical scavengers. A, Soluble AGE BSA or control BSA at 100 g/ml, or no treatment, was added to duplicate wells of confluent primary cultures of human fibroblasts (CRL-2097 cells) under serum-free conditions. In other wells BSA was added that had previously been coincubated with glucose and aminoguanidine before dialysis, as described in Materials and Methods. Total RNA was collected at 48 h, and CTGF mRNA was determined by quantitative RT-PCR in triplicate for each sample. The CTGF mRNA level is expressed in arbitrary units. Data are the mean Ϯ 1 SD from three independent experiments. **, P Ͻ 0.01 vs. all other treatments. B, Wells were preincubated with anti-AGE polyclonal neutralizing IgG, anti-RAGE polyclonal neutralizing IgG (each at 100 g/ml IgG), or 100 g/ml normal rabbit serum (NRS) IgG for 2 h. Soluble AGE BSA or control BSA at 100 g/ml was then added to the wells. Total RNA was collected at 48 h, and IGFBP-rP2 (CTGF) mRNA was determined by quantitative RT-PCR in triplicate for each sample. Data are the mean Ϯ 1 SD from four independent experiments. *, P Ͻ 0.05; **, P Ͻ 0.01 (vs. AGE BSA added alone). C, Duplicate wells of human fibroblasts under serum-free conditions were incubated with serum-free medium alone, 20 mM N-acetyl cysteine, or 100 mM dimethylsulfoxide (DMSO) for 2 h. Soluble AGE BSA or control BSA at 100 g/ml was then added to the wells. Total RNA was collected at 48 h, and CTGF (IGFBP-rP2) mRNA was determined by quantitative RT-PCR in triplicate for each sample. The mRNA levels are expressed in arbitrary units. Data are the mean Ϯ 1 SD from three independent experiments.
anti-RAGE IgG by 64.1%, on the average (Fig. 4B ). Higher concentrations of anti-RAGE IgG did not have any additional effect (not shown). In contrast, the AGE effect was not significantly inhibited by normal rabbit serum IgG (Fig. 4B) . These results show that RAGE is at least partly mediating the AGE induction of CTGF mRNA in the fibroblasts.
As reactive oxygen (RO) species are commonly generated in cells after activation of AGE receptors by its ligand (9, 37) , an effect of inhibiting RO species formation during AGE treatment was studied. Preincubation of the fibroblasts with the antioxidants dimethylsulfoxide or N-acetyl cysteine, however, did not inhibit the increases in CTGF mRNA (Fig.  4C) . These results imply that RO species are unlikely to play a role in the observed AGE effect on CTGF.
A potential role for autocrine TGF␤1 in CTGF mRNA induction by AGE was then examined. TGF␤1 is a potent inducer of CTGF gene expression in this cell system (Fig. 3A) , and in addition, AGE may induce TGF␤1 mRNA and protein in some cells (13) . Induction of CTGF mRNA by rhTGF␤1 added to the cultured fibroblasts was fully inhibited by a TGF␤1-neutralizing antibody at 24 h (Fig. 5A) and 48 h (Fig.  5B) . In contrast, when the same antibody was added under the same conditions in parallel wells, no significant inhibition of the CTGF mRNA increase induced by AGE occurred (Fig.  5, A and B) , indicating that the effect of AGE is TGF␤1 independent in this cell system.
The fibroblast cellular protein from CRL-2097 skin fibroblasts was then analyzed to determine whether AGE treatment causes increases in CTGF protein as well as increases in steady state CTGF mRNA levels. By Western immunoblot after SDS-PAGE, using a polyclonal IGFBP-rP2 (CTGF) antiserum (25) , CTGF steady state protein levels over days 1-3 in the conditioned medium were increased in response to AGE BSA, compared with control BSA treatment (Fig. 6A) . A progressive increase in intact CTGF as well as previously described lower M r immunoreactive forms, at approximately 14 and 20 kDa (38), occurred (Fig. 6A) . High M r immunoreactive material (Ͼ80 kDa) was also more prominent in the AGE-treated medium, which may include CTGF covalently cross-linked by AGE. All of these increases were more marked using AGE BSA synthesized from glycolaldehyde compared with AGE BSA synthesized from glucose (not shown). Using densitometric analysis from three independent experiments, the intact CTGF in the medium was increased by AGE compared with control BSA treatment (mean Ϯ sem) by 3.6 Ϯ 1.1-fold on day 1, 8.0 Ϯ 1.3-fold on day 2, and 14.5 Ϯ 3.1-fold on day 3 (P Ͻ 0.05 for all days of AGE treatment compared with control BSA treatment).
As CTGF is an extracellular matrix and cell-associated signaling protein and also exists in cell media (38) , analysis of whole cell lysates for CTGF protein after AGE treatment was performed. Western immunoblot analysis of the whole cell lysates after SDS-PAGE showed that intact CTGF was increased by AGE treatment from day 3 compared with control BSA treatment (Fig. 6B) . There was no CTGF fragment or high M r immunoreactive material observed in the lysates (not shown). Densitometric analysis of CTGF from lysates from four independent experiments (mean Ϯ sem) gave the following results for fold change with AGE treatment compared with control BSA treatment: 0.89 Ϯ 0.33 on day 1, 0.97 Ϯ 0.17 on day 2, and 1.53 Ϯ 0.25 on day 3 (P Ͻ 0.05 for day 3 only for AGE compared with control BSA on the respective day).
Considering that the increase in CTGF in whole cell lysates on day 3 after AGE treatment was relatively modest, changes in cell lysate CTGF were further determined by a CTGF ELISA, as described in Materials and Methods. This assay can measure endogenous intact CTGF, which is present in whole cell lysates, but due to a lack of parallelism with the intact rhCTGF used as the standard, it cannot be used to accurately measure the 14-kDa CTGF fragment (Fig. 7A) , which is present in the fibroblast-conditioned media (Fig. 6A) . Consistent with the Western immunoblots of cell lysates (Fig. 6B) , the ELISA also showed that AGE treatment reproducibly increased CTGF in the fibroblast whole cell lysates on day 3 (Fig. 7B) . Thus, in contrast to the increases in CTGF protein observed in the conditioned media, there was no increase in CTGF protein in the first 2 days after AGE treatment in the whole cell lysates compared with control, and there was only a modest and delayed increase in CTGF in the lysates, which was much less striking than the increases in CTGF protein observed in the conditioned media (Fig. 6A) .
To determine whether the increase in CTGF in the whole cell lysates seen by day 3 of AGE treatment was accessible to the extracellular environment, a cell association assay for CTGF was performed, as described in Materials and Methods. This assay uses binding of a biotinylated CTGF primary antibody to endogenous CTGF protein, followed by antibody detection using a streptavidin-HRP system. As no plasma membrane-permeabilizing agents were used in the protocol, the specific signal detected by the CTGF primary antibody was due to CTGF present on the cell surface or in the extracellular matrix, rather than CTGF present in an intracellular compartment. As shown in Fig. 7C , at 72 h AGE at 100 g/ml specifically increased the absorbance signal compared with control (P Ͻ 0.05 for analysis of combined data from four independent experiments). In parallel wells, under the same conditions of confluent cell monolayers in serumfree media, cell number determined by hemocytometer counting and trypan blue exclusion was not changed by AGE treatment compared with control BSA (not shown). Thus, these results indicate that at 72 h, AGE treatment increases cell-associated CTGF compared with BSA control treatment alone.
Discussion
This study describes the up-regulation of CTGF mRNA and protein by treatment of human skin fibroblasts with advanced glycosylation end products. The effect of AGE on CTGF induction was caused by products of nonenzymatic glycosylation, as coincubation of aminoguanidine, an inhibitor of nonenzymatic glycosylation, with glucose and BSA did not have an effect on CTGF mRNA, nor was an effect seen with increasing control BSA alone. The up-regulation of CTGF in this cell model was mediated by AGE rather than by earlier products of nonenzymatic glycosylation, such as amadori products, as the use of an antibody specific for AGE that does not bind amadori products inhibited the induction of CTGF gene expression. The effect was at least partly mediated through the AGE receptor known as RAGE, as an anti-RAGE antibody significantly attenuated the effect of AGE on CTGF.
The up-regulation of CTGF by AGE appears to be specific for CTGF and is generalizable to skin fibroblasts from dif- fering sources and passage number. In each of the four fibroblast cell lines studied, AGE up-regulated CTGF. In the cell line most extensively studied, CRL-2097, CTGF was regulated by AGE in early passages (passage 4) and also at later passages (passage 12). In contrast to effects on CTGF, the two other members of the IGFBP superfamily that were studied, IGFBP-3 and IGFBP-rP1, were not up-regulated by AGE. Further studies will be required to determine whether AGE affects other members of the CCN (CTGF, Cyrbl, Nov) family.
The concentrations of AGE BSA used in these experiments approximate those used in vitro in other studies exploring biological effects of AGE on cells (13, 27) . Although there is no universal standard method for measuring specific AGE components at this time, and the AGE antibodies used in assays measuring AGE differ (39) , the AGE BSA concentrations studied are in the broad range for AGE concentrations found in diabetic serum (40) .
Few AGE components have been defined biochemically to date, and the specific end-product(s) that might be mediating the effect on CTGF was not identified in this work. AGE adducts existing in diabetic tissues that have been shown to signal through AGE receptors include mainly CML (28) and imidazoline-based products (41) . Considering that CML adduct is a ligand for RAGE (28) , that our AGE reagent contained CML, and that at least part of the AGE effect on CTGF has been shown to be mediated through RAGE, it is plausible that CML adducts are one of the AGE components operative in this study. In the current work, when AGE BSA synthesized from glycolaldehyde was studied in experiments where AGE BSA synthesized from glucose was also used in treatments, each at the same AGE concentration of 100 g/ml BSA with mRNA measurements over 3 sequential days, the induction of CTGF mRNA by these reagents did not differ (data not shown). As these two AGE reagents contain differing amounts of CML (as described in Materials and Methods), the CML adduct cannot be the only explanation for the observed AGE effect on CTGF mRNA in these AGE preparations. Further experiments with pure CML and other pure AGE adducts, when available, will be required to address this issue.
A number of subtypes of cell surface receptor bind AGE specifically and are responsible for mediating multiple cellular effects of AGE (42) . These receptors exist in four main classes: RAGE, AGE-R1, AGE-R2, and AGE-R3 (8) . In the diabetic environment, the increased AGE present is hypothesized to bind and activate AGE receptors, and in some studies, the induction of growth factors by AGE has been shown to be mediated by AGE receptors, including RAGE (43) . Our studies indicate that RAGE is responsible for mediating at least part of the effect of AGE on CTGF mRNA. The   FIG. 7 . Whole cell lysate and cell-associated increases in CTGF (IGFBP-rP2) after AGE BSA treatment. A, CTGF (IGFBP-rP2) ELISA as described in Materials and Methods, showing the standard curve generated for intact CTGF (IGFBP-rP2; Ⅺ) compared with the curves generated with a 14-kDa fragment of CTGF (IGFBP-rP2; ‚), endogenous intact CTGF present in 2097 cell-conditioned medium (छ), and 2097 cell whole cell lysates (E). B, Results of analysis of CTGF in the whole cell lysates by CTGF ELISA after treatment up to 72 h with AGE or control BSA, each at 100 g/ml. Data are the mean Ϯ 1 SD of four independent experiments. *, P Ͻ 0.05 vs. control BSA on day 3. C, Results showing cell-associated CTGF after AGE treatment compared with control BSA (100 g/ml) at 72 h, using biotinylated anti-CTGF IgG primary antibody followed by HRPlabeled secondary antibody or the secondary antibody alone, as described in Materials and Methods. Data are the mean Ϯ 1 SD of four independent experiments. *, P Ͻ 0.05 vs. all other groups.
possibility that other AGE receptors might also contribute to these effects is not excluded by this work.
A role for growth factors in contributing to chronic diabetes-related end-organ complications, particularly vascular endothelial growth factor (VEGF), TGF␤1, IGF-I, and platelet-derived growth factor, is under increasing evaluation, and a potential role for CTGF in chronic diabetic complications is emerging. CTGF is a potent profibrotic agent (18, 44) , which is reflected in its ability to induce ECM components and increase fibroblast DNA synthesis (18) and to promote angiogenesis (20, 21) . CTGF mRNA levels are up-regulated in many chronic disease states where fibrosis is prominent (22) (23) (24) . Two separate studies involving renal mesangial cells and differing diabetic rat models recently reported that CTGF gene expression (45) as well as protein (46) are increased in mesangial cells after exposure to high glucose and in vivo in diabetic rat kidneys. Immunohistochemical studies of kidney tissue in human end-stage renal disease showed increased CTGF protein in diabetic kidneys as well as other nephropathies (47) , and CTGF mRNA is markedly increased in advanced atheromatous lesions (48) . This is the first report of CTGF induction by advanced glycosylation end products, and it provides a potentially critical linkage among AGE, growth factors, and fibrosis. AGE induction of growth factors and cytokines has been described for VEGF, TGF␤1, IGF-I and platelet-derived growth factor, TNF␣, IL-1␤, and IL-6 (3) mainly in various endothelial and mesenchymal cultured cells and in some cases by AGE administration in vivo (15) . CTGF appears to fit well into this group of proinflammatory and/or profibrotic proteins.
The striking persistent effect over 3 days of AGE on CTGF mRNA even after transient treatment suggests that regulation of CTGF by the AGE reagent tested is complex and may involve multiple interrelated intracellular signals. The cellular mechanism of AGE induction of CTGF mRNA was not defined in this study. RO species were not implicated, because antioxidants were ineffective in inhibiting AGE induction of CTGF. TGF␤1 is a known potent inducer of CTGF gene expression, and CTGF is implicated as a downstream mediator of TGF␤1 effects (49) , particularly in fibrosis (44) . We were unable to show, however, that TGF␤1 is a mediator in the AGE induction of CTGF. In the current work, both the early time course of initial induction of CTGF mRNA by AGE at 8 h as well as the inability of TGF␤1-neutralizing antibodies to inhibit AGE induction of CTGF suggest that AGE is operating through mechanisms that are independent of TGF␤1. Although studies involving the use of exogenously added neutralizing antibodies have potential limitations in assessing the role of endogenous protein bioactivity, that total TGF␤1 measurements in conditioned media measured by TGF␤1 ELISA (Promega Corp., Madison, WI) in these cells were not increased by AGE compared with control BSA treatment (data not shown) is also supportive that TGF␤1 is not a mediator of AGE induction of CTGF in this work. These results contrast with studies describing TGF␤-dependent effects of glucose on CTGF up-regulation in human mesangial cells (45, 46) , but are consistent with other studies showing that various reagents can potently up-regulate CTGF mRNA independently of TGF␤1 (50) .
In human fibroblast primary cultures, CTGF exists at very low levels in conditioned medium and is often present in low M r fragment forms, which may also have bioactivity (38) . That intact CTGF was readily detectable in the medium after AGE treatment may be partly related to posttranslational modification of CTGF, with cross-linking of CTGF protein by AGE into a high M r immunoreactive form and redistribution of CTGF from a cell-associated site into the conditioned medium. In addition to the CTGF increases in the conditioned medium and consistent with the progressive increase in CTGF mRNA after AGE treatment, AGE caused increases in intact CTGF in whole cell lysates at 72 h. Further analysis showed that the CTGF increase in the lysates included protein that was cell associated and in a site accessible to the extracellular environment. To what extent the bioactivity of CTGF protein is affected by its presence in the medium compared with a cell-associated site is an important issue for future study of CTGF bioactivity.
There is a rationale to potentially link AGE effects and diabetic complications with the induction of CTGF in skin and, by association, with pathology in other tissues. A feature commonly present in human diabetes, even in late childhood and adolescence, is skin thickening and contracture (51), termed diabetic sclerosis. This process affects mainly the distal extremities and is characterized by expansion of extracellular matrix, fibroblast proliferation, and angiogenesis (52) . The presence of overt diabetic sclerosis of skin is correlated with the presence and future development of endorgan complications, particularly diabetic nephropathy and retinopathy (53) . AGE products are increased in human diabetic skin (6) , and the levels of AGE in skin also correlate positively with the presence of diabetic microvascular kidney and eye disease (5, 6) . That the ability of CTGF to induce fibrosis has been well characterized in skin (18, 44) makes skin fibroblasts a relevant cell model for the current study.
Clearly, in vivo and longer term studies are required to substantiate a more definitive role for induction of CTGF by AGE in potentially mediating diabetic fibrotic complications in skin and other organs. Activation of receptors for AGE, particularly RAGE (54), has also been implicated in the pathogenesis of fibrosis that develops in chronic diseases other than diabetes (42, 54, 55) . That AGE up-regulates CTGF in nontransformed human fibroblasts suggests that CTGF may be a factor mediating the observed AGE and RAGE effects, which is a hypothesis that requires further testing.
